DNTH
Dianthus Therapeutics, Inc. NASDAQ Listed Jun 21, 2018$85.82
Mkt Cap $3.3B
52w Low $16.64
86.6% of range
52w High $96.50
50d MA $81.11
200d MA $48.02
P/E (TTM)
-20.8x
EV/EBITDA
-8.5x
P/B
6.7x
Debt/Equity
0.0x
ROE
-32.9%
P/FCF
-12.0x
RSI (14)
—
ATR (14)
—
Beta
0.21
50d MA
$81.11
200d MA
$48.02
Avg Volume
976.7K
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
7 Times Square · New York City, NY 10036 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.98 | -1.43 | -45.9% | 79.23 | +2.3% | +9.7% | -1.2% | -6.4% | -3.1% | +0.2% | — |
| Nov 5, 2025 | AMC | -0.86 | -0.97 | -12.8% | 33.73 | +0.4% | +8.0% | -0.4% | +0.9% | -1.4% | +7.3% | — |
| Aug 7, 2025 | AMC | -0.86 | -0.88 | -2.3% | 19.15 | -0.8% | -2.0% | +0.7% | +5.3% | +4.8% | -2.9% | — |
| May 12, 2025 | AMC | -0.86 | -0.82 | +4.7% | 20.08 | -2.6% | -6.2% | +0.3% | -0.8% | +5.0% | -2.1% | — |
| Mar 11, 2025 | AMC | -0.85 | -0.81 | +4.7% | 23.38 | -6.5% | -6.3% | -2.8% | +0.2% | +3.0% | -5.6% | — |
| Nov 7, 2024 | AMC | -0.59 | -0.74 | -25.4% | 29.90 | +7.9% | -2.8% | -4.5% | -0.3% | -4.8% | -3.3% | — |
| Aug 8, 2024 | AMC | -0.50 | -0.51 | -2.0% | 26.74 | +1.0% | +2.8% | -3.7% | +0.0% | +7.7% | +4.6% | — |
| May 9, 2024 | AMC | -0.43 | -0.54 | -25.6% | 24.93 | +6.2% | -2.6% | +7.1% | +7.4% | -0.9% | -5.2% | — |
| Mar 21, 2024 | AMC | -1.11 | -0.71 | +36.0% | 27.94 | +6.0% | +14.3% | -3.0% | +1.7% | -2.9% | -2.0% | — |
| Nov 9, 2023 | AMC | -0.51 | -3.78 | -641.2% | 11.41 | +0.8% | +0.8% | -1.3% | -0.4% | +2.6% | -1.3% | — |
| Aug 3, 2023 | AMC | -0.19 | -0.05 | +73.7% | 13.28 | -2.2% | -3.6% | -0.6% | +0.6% | +0.0% | -1.9% | — |
| Mar 30, 2023 | AMC | -6.40 | -7.70 | -20.2% | 12.33 | -1.5% | +3.2% | -4.7% | +0.3% | -3.5% | +1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $85.84 | $85.53 | -0.4% | -6.4% | -3.1% | +0.2% | +1.2% | -0.1% |
| Mar 10 | Baird | Maintains | Outperform → Outperform | — | $79.23 | $81.08 | +2.3% | +9.7% | -1.2% | -6.4% | -3.1% | +0.2% |
| Mar 10 | Clear Street | Maintains | Buy → Buy | — | $79.23 | $81.08 | +2.3% | +9.7% | -1.2% | -6.4% | -3.1% | +0.2% |
| Mar 10 | Wedbush | Maintains | Outperform → Outperform | — | $79.23 | $81.08 | +2.3% | +9.7% | -1.2% | -6.4% | -3.1% | +0.2% |
| Mar 10 | Raymond James | Upgrade | Outperform → Strong Buy | — | $79.23 | $81.08 | +2.3% | +9.7% | -1.2% | -6.4% | -3.1% | +0.2% |
| Mar 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $65.20 | $78.90 | +21.0% | +21.5% | +9.7% | -1.2% | -6.4% | -3.1% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.20 | $78.90 | +21.0% | +21.5% | +9.7% | -1.2% | -6.4% | -3.1% |
| Mar 9 | Truist | Maintains | Buy → Buy | — | $65.20 | $78.90 | +21.0% | +21.5% | +9.7% | -1.2% | -6.4% | -3.1% |
| Mar 4 | Guggenheim | Maintains | Buy → Buy | — | $55.39 | $58.45 | +5.5% | +12.0% | -1.0% | +6.1% | +21.5% | +9.7% |
| Feb 11 | Wedbush | Maintains | Outperform → Outperform | — | $50.82 | $50.86 | +0.1% | -1.8% | -4.9% | -0.2% | +3.8% | -3.5% |
| Feb 2 | Jefferies | Maintains | Buy → Buy | — | $53.39 | $53.25 | -0.3% | -0.4% | -1.4% | -8.3% | -3.2% | +9.0% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $38.09 | $38.02 | -0.2% | +0.1% | +0.2% | +2.4% | +14.7% | +3.2% |
| Dec 22 | Wedbush | Maintains | Outperform → Outperform | — | $42.44 | $42.50 | +0.1% | +3.1% | -2.7% | +1.3% | -3.1% | -0.5% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.28 | $37.38 | +3.0% | +0.9% | -1.4% | +7.3% | -8.3% | +15.1% |
| Nov 6 | Wedbush | Maintains | Outperform → Outperform | — | $33.73 | $33.85 | +0.4% | +8.0% | -0.4% | +0.9% | -1.4% | +7.3% |
| Sep 12 | Wedbush | Maintains | Outperform → Outperform | — | $37.86 | $38.47 | +1.6% | -1.8% | -0.3% | +1.2% | +3.8% | -0.0% |
| Sep 12 | Stifel | Maintains | Buy → Buy | — | $37.86 | $38.47 | +1.6% | -1.8% | -0.3% | +1.2% | +3.8% | -0.0% |
| Sep 9 | Raymond James | Maintains | Outperform → Outperform | — | $31.80 | $31.73 | -0.2% | +11.9% | +6.6% | -0.1% | -1.8% | -0.3% |
| Sep 9 | Baird | Maintains | Outperform → Outperform | — | $31.80 | $31.73 | -0.2% | +11.9% | +6.6% | -0.1% | -1.8% | -0.3% |
| Sep 9 | Guggenheim | Maintains | Buy → Buy | — | $31.80 | $31.73 | -0.2% | +11.9% | +6.6% | -0.1% | -1.8% | -0.3% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.50 | $25.03 | -5.5% | +20.0% | +11.9% | +6.6% | -0.1% | -1.8% |
| Aug 21 | Wedbush | Maintains | Outperform → Outperform | — | $23.42 | $23.71 | +1.2% | +1.0% | +2.7% | -3.7% | +3.9% | -0.4% |
| May 13 | Baird | Maintains | Outperform → Outperform | — | $20.08 | $19.56 | -2.6% | -6.2% | +0.3% | -0.8% | +5.0% | -2.1% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.08 | $19.56 | -2.6% | -6.2% | +0.3% | -0.8% | +5.0% | -2.1% |
| May 13 | Wedbush | Maintains | Outperform → Outperform | — | $20.08 | $19.56 | -2.6% | -6.2% | +0.3% | -0.8% | +5.0% | -2.1% |
| Mar 12 | Guggenheim | Maintains | Buy → Buy | — | $23.38 | $21.85 | -6.5% | -6.3% | -2.8% | +0.2% | +3.0% | -5.6% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.38 | $21.85 | -6.5% | -6.3% | -2.8% | +0.2% | +3.0% | -5.6% |
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $23.38 | $21.85 | -6.5% | -6.3% | -2.8% | +0.2% | +3.0% | -5.6% |
| Nov 11 | Oppenheimer | Maintains | Outperform → Outperform | — | $29.06 | $29.94 | +3.0% | -4.5% | -0.3% | -4.8% | -3.3% | -8.4% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.06 | $29.94 | +3.0% | -4.5% | -0.3% | -4.8% | -3.3% | -8.4% |
| Nov 8 | Raymond James | Maintains | Outperform → Outperform | — | $29.90 | $32.25 | +7.9% | -2.8% | -4.5% | -0.3% | -4.8% | -3.3% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.69 | $26.96 | +1.0% | +1.2% | +0.8% | +0.5% | +1.8% | +0.4% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.50 | $27.53 | +0.1% | -3.7% | +0.0% | +7.7% | +4.6% | -3.6% |
| Aug 9 | Wedbush | Maintains | Outperform → Outperform | — | $26.74 | $27.00 | +1.0% | +2.8% | -3.7% | +0.0% | +7.7% | +4.6% |
| May 10 | Wedbush | Maintains | Outperform → Outperform | — | $24.93 | $26.48 | +6.2% | -2.6% | +7.1% | +7.4% | -0.9% | -5.2% |
| Apr 18 | Raymond James | Maintains | Outperform → Outperform | — | $23.34 | $24.36 | +4.4% | +1.2% | -1.6% | -0.0% | +0.8% | -9.0% |
| Mar 22 | Wedbush | Maintains | Outperform → Outperform | — | $27.94 | $29.63 | +6.0% | +14.3% | -3.0% | +1.7% | -2.9% | -2.0% |
| Mar 22 | Jefferies | Maintains | Buy → Buy | — | $27.94 | $29.63 | +6.0% | +14.3% | -3.0% | +1.7% | -2.9% | -2.0% |
| Jan 26 | Wedbush | Maintains | Outperform → Outperform | — | $17.85 | $17.99 | +0.8% | +0.2% | +7.4% | +1.4% | -2.4% | +9.1% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Dianthus is presenting corporate strategy details, likely including pipeline updates for lead candidates Claseprubart and DNTH212, which investors should monitor for clinical progress or commercialization timeline clarity.
Mar 26
8-K
Unknown — 8-K Filing
DNTH issued pre-funded warrants allowing holders to accumulate up to 19.99% ownership with 61-day notice, indicating significant dilution risk and potential control shifts for existing shareholders.
Mar 12
8-K · 8.01
!! High
Dianthus Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Dianthus Therapeutics advanced claseprubart to Phase 3 following positive interim data in its CIDP trial, signaling regulatory confidence and potential path toward approval for this neuropathy treatment.
Mar 9
Data updated apr 25, 2026 5:32am
· Source: massive.com